115 related articles for article (PubMed ID: 36682291)
1. A-ring-fused pyrazoles of dihydrotestosterone targeting prostate cancer cells via the downregulation of the androgen receptor.
Peřina M; Kiss MA; Mótyán G; Szczyrbová E; Eliáš M; Študent V; Kurfürstová D; Kovalová M; Mada L; Bouchal J; Frank É; Jorda R
Eur J Med Chem; 2023 Mar; 249():115086. PubMed ID: 36682291
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of dihydrotestosterone derivatives modified in the A-ring with (hetero)arylidene, pyrazolo[1,5-a]pyrimidine and triazolo[1,5-a]pyrimidine moieties and their targeting of the androgen receptor in prostate cancer.
Kiss MA; Peřina M; Bazgier V; May NV; Baji Á; Jorda R; Frank É
J Steroid Biochem Mol Biol; 2021 Jul; 211():105904. PubMed ID: 33933576
[TBL] [Abstract][Full Text] [Related]
3. Dihydrotestosterone-based A-ring-fused pyridines: Microwave-assisted synthesis and biological evaluation in prostate cancer cells compared to structurally related quinolines.
Kiss MA; Peřina M; Bereczki L; Baji Á; Bělíček J; Jorda R; Frank É
J Steroid Biochem Mol Biol; 2023 Jul; 231():106315. PubMed ID: 37086925
[TBL] [Abstract][Full Text] [Related]
4. Anti-Cancer Activity of Novel Dihydrotestosterone-Derived Ring A-Condensed Pyrazoles on Androgen Non-Responsive Prostate Cancer Cell Lines.
Mótyán G; Gopisetty MK; Kiss-Faludy RE; Kulmány Á; Zupkó I; Frank É; Kiricsi M
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052484
[TBL] [Abstract][Full Text] [Related]
5. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
6. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
Mukherjee B; Mayer D
Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
[TBL] [Abstract][Full Text] [Related]
7. Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
Jorda R; Lopes SMM; Řezníčková E; Ajani H; Pereira AV; Gomes CSB; M V D Pinho E Melo T
Eur J Med Chem; 2019 Sep; 178():168-176. PubMed ID: 31181481
[TBL] [Abstract][Full Text] [Related]
8. Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone.
Chhipa RR; Lee KS; Onate S; Wu Y; Ip C
Mol Cancer Res; 2009 Sep; 7(9):1543-52. PubMed ID: 19737972
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
[TBL] [Abstract][Full Text] [Related]
10. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms.
Jia L; Kim J; Shen H; Clark PE; Tilley WD; Coetzee GA
Mol Cancer Res; 2003 Mar; 1(5):385-92. PubMed ID: 12651911
[TBL] [Abstract][Full Text] [Related]
12. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibition of androgen-responsive prostate cancer cells with brefeldin A targeting cell cycle and androgen receptor.
Rajamahanty S; Alonzo C; Aynehchi S; Choudhury M; Konno S
J Biomed Sci; 2010 Jan; 17(1):5. PubMed ID: 20102617
[TBL] [Abstract][Full Text] [Related]
14. Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression.
Fuse H; Korenaga S; Sakari M; Hiyama T; Ito T; Kimura K; Kato S
Prostate; 2007 May; 67(6):630-7. PubMed ID: 17342748
[TBL] [Abstract][Full Text] [Related]
15. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.
Mohler JL; Titus MA; Bai S; Kennerley BJ; Lih FB; Tomer KB; Wilson EM
Cancer Res; 2011 Feb; 71(4):1486-96. PubMed ID: 21303972
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of androgenic regulation by brefeldin A in androgen-responsive prostate cancer cells.
Alexander B; Fishman AI; Green D; Choudhury MS; Konno S
Urol Oncol; 2013 Jan; 31(1):104-9. PubMed ID: 21795077
[TBL] [Abstract][Full Text] [Related]
17. The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells.
Moss PE; Lyles BE; Stewart LV
Exp Cell Res; 2010 Dec; 316(20):3478-88. PubMed ID: 20932825
[TBL] [Abstract][Full Text] [Related]
18. Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.
Segal CV; Koufaris C; Powell C; Gooderham NJ
Toxicology; 2015 Jul; 333():45-52. PubMed ID: 25846647
[TBL] [Abstract][Full Text] [Related]
19. Exploiting Ligand-binding Domain Dimerization for Development of Novel Androgen Receptor Inhibitors.
Helsen C; Nguyen TT; Lee XY; Eerlings R; Louros N; Schymkowitz J; Rousseau F; Claessens F; Voet A
Mol Cancer Ther; 2022 Dec; 21(12):1823-1834. PubMed ID: 36218067
[TBL] [Abstract][Full Text] [Related]
20. Inverse Regulation of DHT Synthesis Enzymes 5α-Reductase Types 1 and 2 by the Androgen Receptor in Prostate Cancer.
Audet-Walsh É; Yee T; Tam IS; Giguère V
Endocrinology; 2017 Apr; 158(4):1015-1021. PubMed ID: 28324044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
